NIJMEGEN, the Netherlands--(BUSINESS WIRE)--Synthon today announced that the company’s glatiramer acetate met the main endpoint of a late-stage study in patients with relapsing remitting multiple ...

BC Partners to Acquire Synthon International Holding B.V., a Global Market Leader in the Development of Complex Generics London, 2nd July 2019 – Funds advised by BC Partners (“BC Partners”), a leading ...

Under the terms of this agreement, Synthon will be responsible for obtaining final regulatory approval for its Ozanimod Capsules product, and thereafter, for the manufacture and supply of the product.

BC Partners will retain a minority stake in Synthon BC Partners acquired a majority stake in Synthon in 2019 The transaction is expected to close in the second quarter of 2025 BC Partners has agreed ...

NIJMEGEN, The Netherlands--(BUSINESS WIRE)--The Supervisory Board of Synthon BV, an international, science-centered pharmaceutical company specialized in developing and manufacturing high-quality ...

NEW YORK & NIJMEGEN, Netherlands--(BUSINESS WIRE)--Pfizer Inc. and Synthon, an international pharmaceutical company specializing in the development of complex generic medicines, today announced they ...

Generic drug company Synthon Pharmaceuticals has received tentative U.S. Food and Drug Administration approval on its application to make a version of UCB‘s (EBR:UCB) allergy medicine Xyzal.

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Goldman Sachs Asset Management has agreed a more than €2bn deal to acquire drugmaker Synthon from BC Partners, ...

“Trastuzumab is one of the most advanced biopharmaceutical products of Synthon’s pipeline, and is now ready to go into a confirmatory phase III clinical trial in breast cancer patients,” says Rudy ...